The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
July 14th 2025
Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.
Trastuzumab Deruxtecan Improves Progression-Free Survival for Certain Patients With Breast Cancer
August 11th 2021The Independent Data Monitoring Committee concluded that DESTINY-Breast03 met the primary endpoint of progression-free survival and showed a highly statistically significant and clinically meaningful improvement for patients with human epidermal growth factor receptor 2 (HER2)-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.
Read More
Webcast: The Impact of Environmental Conditions on Patient Health
August 10th 2021A panel of key stakeholders in the pharmacy field discuss the nature of environmental conditions as a social determinant of health and the potential impact on patient health outcomes, as well as how to best educate patients and colleagues when approaching the subject in the pharmacy.
Watch
Multimorbidity, health-related quality of life, and stigma and discrimination continue to be major issues for people living with HIV, including those who have achieved viral suppression, according to a consensus statement from a multidisciplinary panel of HIV experts published in Nature Communications.
Read More
The investigators found that the combination of cemiplimab-rwlc and chemotherapy resulted in a substantial improvement in OS compared to chemotherapy alone for patients with metastatic or locally advanced disease and tumors with either squamous or non-squamous histology and across all programmed death-ligand 1 expression levels.
Read More
5-Day Radiation Regimen Safe, Effective for Individuals With Severe Prostate Cancer
August 5th 2021According to the investigators, the findings demonstrate that a 5-day regimen of stereotactic body radiotherapy, a form of external beam radiation therapy that uses a higher dose of radiation, had a 4-year cure rate of 82%.
Read More
FDA Grants Atezolizumab Priority Review as Adjuvant Treatment for Certain Patients With NSCLC
August 3rd 2021According to a press release from Roche, the FDA is reviewing the company’s Biologics License Application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.
Read More
Novel Drug Combination Serves as Potential Treatment for Acute Myeloid Leukemia
August 3rd 2021MDM2 inhibitors and BET inhibitors, which show limited efficacy against acute myeloid leukemia (AML) as monotherapies, are potent against AML when used in combination, according to a study published in Nature Communications.
Read More